“Electronic Nose” Predicts Immunotherapy Response
An “electronic nose,” or eNose, accurately predicted whether patients with advanced non–small cell lung cancer would respond to anti–programmed cell death 1 (anti-PD-1) therapies in a recent observational study published in the Annals of Oncology. If the findings bear out in randomized clinical trials, the device could spare patients with cancer from receiving immunotherapies that won’t benefit them.
Source: JAMA - Category: General Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | General Medicine | Immunotherapy | Lung Cancer | Study